''Labels'' for medicines are also known as the ''package inserts'' that list the details of the approval granted by regulatory authorities such as the FDA (U.S. Food and Drug Administration) for the sale of medicines by the pharmaceutical industry. ''Off-label'' means utilizing an approved medicine in a manner not contained in the approved ''label.'' Although it is illegal for employees of the pharmaceutical industry to promote ''off label'' use of their medicine, it is not illegal for licensed practitioners to prescribe off-label. In fact, the majority of the practice of psychiatry, [1] [2] [3] neurology, 4 pain medicine, 5 oncology, and of many other specialties 6 whose clinicians practice in the real world (rather than in clinical trial settings) is off-label, and in one of five categories listed in Table 1 . It has been said that more than 80% of psychiatric diagnoses have no FDA-approved medical treatments, 2 a number that is likely to be even greater now with the recent launch of the new DSM 5 (Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, 5th edition). Thus, it is more important than ever for prescribers to know the rules, 7-10 the risks (Table 2) , and the benefits (Table 3) of off-label prescribing.
Regulating the Sale of Medicine Versus the Practice of Medicine
Recent law suits, scandalous publicity, and eyepopping fines for off-label promotion by the pharmaceutical industry in recent years have led to tightening of the standards for the sale of medicine as well as confusion and even fear about whether the longstanding practice of off-label prescribing of drugs in clinical practice can continue. This situation has also led to pressure on prescribers by various stakeholders to adhere to the same standards imposed on pharmaceutical sales personnel: by payers who wish to exploit labels in order to restrict the use of expensive medications to save them costs, and by government agencies and academics-most of whom are not in current clinical practice in the real world-who wish to exploit labels to promote elite guidelines only at the top of the pyramid of ''evidence-based medicine'' (see Figure 1 ). Although it is laudable to save costs whenever possible and to practice according to the best available evidence, what is a practitioner to do when there is no evidence from the top of the pyramid for a given patient, but there is evidence other than that derived from meta-analyses of large, randomized, controlled clinical trials, which mostly come from labels? This situation of ''off-label patients'' is common in clinical practice, since it includes patients who have two or more illnesses or who take multiple drugs or who are resistant to prior standard treatments but who were likely excluded from almost all large randomized controlled trials at the top of Figure 1 (see also Table 1 ).
General Guidelines
According to professional societies, including the American Psychiatric Association, 7-10 prescribers can use drugs off-label if the use of the drug is safe and effective in the professional judgment of the prescriber and if it is properly documented. Psychiatrists are notorious for keeping poor records; however, off-label prescribing requires maintaining scrupulous records, including mention of informed consent. Obviously, prescribing off-label should not be done because of incentives provided by a drug company, but only for the benefit of the patient ( that off-label prescribing is for life threatening conditions or for chronic and seriously debilitating conditions. It is also best to check with malpractice liability carriers to be sure that investigational or risky off-label prescribing is covered.
Off-Label Treatment Is Personalized Medicine
Evidence-based medicine is population-based medicine, whereas the practice of medicine is practiced one patient at a time, sometimes called personalized medicine. 11 What is right for the median patient is not always right for the individual patient, who may be an outlier and require customized treatment based on past treatment successes and failures, family history, and, increasingly, biomarkers (Table 1) . 11 On the one hand, evidence-based treatment guidelines derived from the label define where to start for the ' Ability to use agents in comorbid, complex, or treatment-resistant patients not studied in controlled trials ' Ability to practice personalized medicine typical patient included in the trials for that medication. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] On the other hand, treating everyone as a median patient in a population of patients that actually excludes many individuals that a typical practitioner must treat (Table 1) can force a practitioner to treat everyone the same and in lock-step with guidelines that do not apply to many patients who themselves are off-label. Treating all patients only according to labels and only according to the results of large randomized clinical trials in simplified patient populations is a situation sometimes called the ''tyranny of the majority.'' 11 Unless a more customized approach is available from off-label prescribing to such off-label patients, many real-world patients will not have effective treatments for their off-label condition (Table 1 ). In addition, the results of empirical trial-and-error treatment of such off-label individuals and from consulting the literature, as well as practice standards for how a reasonable practitioner in a given field of medicine and in a given geographic area manages the specific patients who are in the off-label situations shown in Table 1 , are good tips for how to proceed.
Don't Be Fool
There are dangers of going too far and relying only on case-based/narrative-based evidence or opinion alone (Table 4) . 12, 13 It may be particularly important to remember the following when going ''off label'':
> Radiance of gray hair is not proportional to an understanding of the facts > Eloquence, smoothness of the tongue, and sartorial elegance cannot change reality > Qualifications and past accomplishments do not signify a privileged access to the truth > Experts almost always have conflicts of interest > Clinical acumen is not measured in frequent flier miles 13 Now more than ever, there is the need for prudent, well-reasoned off-label prescribing in order to help many if not the majority of patients. As the pace of new drugs entering clinical practice slows down considerably, an increasing majority of all drugs will become generic-none of which will have any incentive or mechanism to update their labels. For the majority of drugs, therefore, the labels we have now are going to be the labels we have forever, despite any future advances in medical therapeutics for these agents. Furthermore, as we enter the era of genetic markers, new research findings will increasingly identify individuals who need specific drugs, at specific doses, and perhaps in specific combinations. However, these guidelines will find themselves into labels only for new drugs and not for any generic agents. Thus, mindful clinicians who follow the literature and who learn from individual patients will want to keep off-label prescribing as a properly honed and potentially powerful tool within their armamentarium of best practices. Table 4 . Seven alternatives to evidence-based medicine to be avoided
